AMGEN presents ‘encouraging’ AMG 133 weight loss resultsAmgen revealed new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist...
ICER finds semaglutide more effective, but more expensiveThe Institute for Clinical and Economic Review (ICER) in the US has published its revised Evidence Report assessing the comparative...
Innovent starts Phase 2 Clinical Trial of mazdutide in Chinese adults with obesityInnovent Biologics has announced that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure2 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity2 days ago